Business Context and Reporting Period
Company: MaxCyte, Inc. (MXCT)
Filing Type: Form 8-K (Current Report)
Date of Report: March 16, 2026
Reporting Period: Event date March 16, 2026
Business Context: The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Rockville, Maryland. Its common stock is registered on The Nasdaq Stock Market LLC under the symbol MXCT.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory listing event rather than financial performance metrics.
Material Changes
Listing Status Change: On March 16, 2026, MaxCyte, Inc. received notice from Nasdaq that it no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
Trigger Event: The closing bid price for the Company's common stock fell below $1.00 per share for 30 consecutive trading days.
Current Status: The notice has no immediate effect on the listing; the stock continues to trade on the Nasdaq Global Select Market.
Guidance, Outlook, and Risks
- Compliance Period: The Company has an initial compliance period of 180 calendar days, ending September 14, 2026, to regain compliance.
- Compliance Requirement: To regain compliance, the closing bid price must meet or exceed $1.00 per share for a minimum of 10 consecutive trading days prior to September 14, 2026.
- Alternative Path: If compliance is not met by the deadline, the Company may apply for an additional 180-day period to transfer listing to the Nasdaq Capital Market, provided it meets other initial listing standards (excluding the bid price requirement) and demonstrates an ability to cure the deficiency.
- Risks: There is no assurance the Company will regain compliance. Failure to do so may result in delisting. The Company retains the right to appeal any delisting determination.
Investor Verification Checklist
- Verify the current closing bid price of MXCT stock to assess proximity to the $1.00 threshold.
- Monitor the stock price for 10 consecutive trading days above $1.00 before the September 14, 2026 deadline.
- Review future filings for any application to transfer listing to the Nasdaq Capital Market if the initial cure period expires without compliance.
- Check for any Nasdaq staff determinations regarding the Company's ability to cure the deficiency.